First Trimester Screening for Preeclampsia and Intrauterine Growth RestrIction Using Three Dimensional Doppler Angiography (SPIRIT)
Primary Purpose
Pre-Eclampsia
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Ultrasound
Blood sample collection
Sponsored by
About this trial
This is an interventional diagnostic trial for Pre-Eclampsia
Eligibility Criteria
Inclusion Criteria:
- Singleton nulliparous pregnant women between 11 and 13+6 gestation weeks.
- Mandatory enrolment in a social security plan,
- Patient (or a third person, independent from the investigator and the sponsor, in case of inability to read or write) having signed an informed consent.
Exclusion Criteria:
- Patients under a measure of legal protection.
- Patient under 18,
- Absence of social insurance,
- Patient participating simultaneously to other interventional research trial to test a pharmaceutical treatment and protocols are not compatible,
- Inability to understand and accept the protocol.
Sites / Locations
- Centre Hospitalier Régional Universitaire de Nancy
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
All patients
Arm Description
All patients will have the same intervention (3DPD and UAD acquisitions ; blood sample)
Outcomes
Primary Outcome Measures
Measure of 3D power Doppler indice : the vascularization index (VI)
Measure of 3D power Doppler indice : the flow index (FI)
Measure of 3D power Doppler indice : the vascularization-flow index (VFI)
Secondary Outcome Measures
Full Information
NCT ID
NCT03342014
First Posted
November 8, 2017
Last Updated
December 9, 2022
Sponsor
Central Hospital, Nancy, France
1. Study Identification
Unique Protocol Identification Number
NCT03342014
Brief Title
First Trimester Screening for Preeclampsia and Intrauterine Growth RestrIction Using Three Dimensional Doppler Angiography
Acronym
SPIRIT
Official Title
First Trimester Screening for Preeclampsia and Intrauterine Growth RestrIction Using Three Dimensional Doppler Angiography (SPIRIT): A Prospective Study in Nulliparous Pregnant Women
Study Type
Interventional
2. Study Status
Record Verification Date
December 2022
Overall Recruitment Status
Completed
Study Start Date
April 16, 2018 (Actual)
Primary Completion Date
November 14, 2022 (Actual)
Study Completion Date
November 14, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Central Hospital, Nancy, France
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Introduction: Preeclampsia (PE) and intrauterine growth restriction (IUGR) are two major pregnancy complications, related to a chronic utero-placental hypoperfusion. Nowadays, there isn't a screening or diagnostic test in clinic for utero-placental vascularization deficiency. Since 2004, 3D Power Doppler angiography has been used for the evaluation of utero-placental vascularisation and three vascular indices have been calculated: the vascularisation index (VI), flow index (FI) and vascularisation-FI (VFI). A high intra and inter-observer reproducibility and its potential interest for placental function study were reported. The investigator's main hypothesis is that these 3DPD indices could provide predictive values for PE and/or IUGR occurrence much higher than those observed with the currents other markers.
Objectives: The main objective of this study is to determine differences in 3DPD indices at first trimester between pregnancies defined at their outcome as uncomplicated pregnancy, PE (mild and severe) and IUGR in nulliparous women.
Methods and analysis: This is a prospective study. The investigators expect to include 2200 women in 4 French centers: Centre Hospitalier Universitaire de Nancy, Paris-Port-Royal (Assistance Publique - Hôpitaux de Paris), Strasbourg and Belfort (Hôpital Nord Franche-Comté).
The nulliparous pregnant women will be recruited during their 1st trimester consultation for routine Down syndrome screening (11-13+6 gestation weeks). Especially for the study, the 3DPD and Uterine Artery Doppler (UAD) acquisition, which last less than 10 min, will be included in the current routine 11-13+6 gestation weeks ultrasound screening. Also, additional blood samples will be taken for biomarker analysis (PAPP-A and P1GF) and biological collection. Utero-placental vascularization indices (VI, FI, VFI) will be quantified using VOCAL® software. For each subgroup (uncomplicated pregnancy, PE and IUGR) mean values in 3DPD indices will be computed and compared using a pairwise t test with a Bonferroni correction p value adjustment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pre-Eclampsia
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
2159 (Actual)
8. Arms, Groups, and Interventions
Arm Title
All patients
Arm Type
Experimental
Arm Description
All patients will have the same intervention (3DPD and UAD acquisitions ; blood sample)
Intervention Type
Device
Intervention Name(s)
Ultrasound
Intervention Description
3DPD and UAD acquisitions (10 min)
Intervention Type
Biological
Intervention Name(s)
Blood sample collection
Intervention Description
A blood sampling (20 mL) is collected for biomarker analysis (PAPP-A and PlGF) and biological collection.
Primary Outcome Measure Information:
Title
Measure of 3D power Doppler indice : the vascularization index (VI)
Time Frame
through study completion, an average of 40 months
Title
Measure of 3D power Doppler indice : the flow index (FI)
Time Frame
through study completion, an average of 40 months
Title
Measure of 3D power Doppler indice : the vascularization-flow index (VFI)
Time Frame
through study completion, an average of 40 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Singleton nulliparous pregnant women between 11 and 13+6 gestation weeks.
Mandatory enrolment in a social security plan,
Patient (or a third person, independent from the investigator and the sponsor, in case of inability to read or write) having signed an informed consent.
Exclusion Criteria:
Patients under a measure of legal protection.
Patient under 18,
Absence of social insurance,
Patient participating simultaneously to other interventional research trial to test a pharmaceutical treatment and protocols are not compatible,
Inability to understand and accept the protocol.
Facility Information:
Facility Name
Centre Hospitalier Régional Universitaire de Nancy
City
Vandoeuvre-lès-Nancy
ZIP/Postal Code
54500
Country
France
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
33077562
Citation
Bertholdt C, Hossu G, Banasiak C, Beaumont M, Morel O. First trimester screening for pre-eclampsia and intrauterine growth restriction using three-dimensional Doppler angiography (SPIRIT): protocol for a multicentre prospective study in nulliparous pregnant women. BMJ Open. 2020 Oct 19;10(10):e037751. doi: 10.1136/bmjopen-2020-037751.
Results Reference
derived
Learn more about this trial
First Trimester Screening for Preeclampsia and Intrauterine Growth RestrIction Using Three Dimensional Doppler Angiography
We'll reach out to this number within 24 hrs